These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8296905)

  • 1. Serotonergic sensitivity in borderline personality disorder: preliminary findings.
    Hollander E; Stein DJ; DeCaria CM; Cohen L; Saoud JB; Skodol AE; Kellman D; Rosnick L; Oldham JM
    Am J Psychiatry; 1994 Feb; 151(2):277-80. PubMed ID: 8296905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
    Simeon D; Hollander E; Stein DJ; DeCaria C; Cohen LJ; Saoud JB; Islam N; Hwang M
    Psychiatry Res; 1995 Sep; 58(2):161-4. PubMed ID: 8570768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
    Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia.
    Brewerton TD; Mueller EA; Lesem MD; Brandt HA; Quearry B; George DT; Murphy DL; Jimerson DC
    Arch Gen Psychiatry; 1992 Nov; 49(11):852-61. PubMed ID: 1444722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT1A dysfunction in borderline personality disorder.
    Hansenne M; Pitchot W; Pinto E; Reggers J; Scantamburlo G; Fuchs S; Pirard S; Ansseau M
    Psychol Med; 2002 Jul; 32(5):935-41. PubMed ID: 12171388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
    Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
    Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
    Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls.
    Paris J; Zweig-Frank H; Kin NM; Schwartz G; Steiger H; Nair NP
    Psychiatry Res; 2004 Jan; 121(3):239-52. PubMed ID: 14675743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
    Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH
    Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients.
    Rinne T; Westenberg HG; den Boer JA; van den Brink W
    Biol Psychiatry; 2000 Mar; 47(6):548-56. PubMed ID: 10715361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse.
    Moss HB; Yao JK; Panzak GL
    Biol Psychiatry; 1990 Aug; 28(4):325-38. PubMed ID: 2397249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
    Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
    Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa.
    Levitan RD; Kaplan AS; Joffe RT; Levitt AJ; Brown GM
    Arch Gen Psychiatry; 1997 Jun; 54(6):521-7. PubMed ID: 9193192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
    Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
    Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects.
    Terao T; Yoshimura R; Ohmori O; Takano T; Takahashi N; Iwata N; Suzuki T; Abe K
    Biol Psychiatry; 1997 May; 41(9):974-8. PubMed ID: 9110103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects.
    George DT; Benkelfat C; Rawlings RR; Eckardt MJ; Phillips MJ; Nutt DJ; Wynne D; Murphy DL; Linnoila M
    Am J Psychiatry; 1997 Jan; 154(1):81-7. PubMed ID: 8988963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
    Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E
    CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen augments serotonergic activity in postmenopausal women.
    Halbreich U; Rojansky N; Palter S; Tworek H; Hissin P; Wang K
    Biol Psychiatry; 1995 Apr; 37(7):434-41. PubMed ID: 7786956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.